Tips and Tricks for Durysta Injection

Put new procedures in place for sustained-release therapy.

By E. Randy Craven, MD

An Update on 24-Hour Glaucoma Monitoring

Current approaches reveal remaining challenges.

By Kaweh Mansouri, MD, MPH, Kevin Gillmann, MD, MBBS, FEBOphth, MArch

Surgical Management of Primary Congenital Glaucoma

Achieving the goal of lifelong vision.

By Hamed Esfandiari, MD

Practical Tips on OCT in Glaucoma

Review the options, uses, and common artifacts.

By Sanjay Asrani, MD, Matthew Duggan, MD

Glauconix Offers Services to Facilitate Drug Development

Human tissue models save time and money.

By Jerry Helzner, contributing editor

From the Editor: Glaucoma Therapy's Fourth Pillar

By Nathan Radcliffe, MD

Coding: MIGS Approved Implants and Compliance

Take a bird's eye view.

By RIVA LEE ASBELL

Dogma vs Data: Prostaglandin Use in Glaucoma Patients With Uveitis

Do prostaglandins increase risk of uveitis flares, macular edema, and herpetic keratouveitis?

By Debra A. Goldstein, MD, Jennifer Lee, MD

Case Files: MIGS in a Glaucoma Patient With Prior Incisional Surgery

Can MIGS be a "Goldilocks" option for refractory glaucoma?

By Brandon Baartman, MD

Product Spotlight: Delivering Treatments Right on the Mark

Nidek's newly upgraded laser ensures precise targeting of pathology.

By Karen Appold, contributing writer

Personalized Coaching Improves Medication Compliance

By Jerry Helzner, contributing editor

Study Reveals How the Eye Regulates IOP

By Jerry Helzner, contributing editor

Implandata Launches Remote IOP Monitoring

By Jerry Helzner, contributing editor

MicroPulse Effective in Trans-scleral Cyclophotocoagulation

By Jerry Helzner, contributing editor

Sight Sciences Introduces Improved OMNI System

By Jerry Helzner, contributing editor

Efficacy of SLT as First-Line Therapy

By Jerry Helzner, contributing editor

Identifying Cell Degeneration in Glaucoma

By Jerry Helzner, contributing editor

FDA Will Review Santen MicroShunt

By Jerry Helzner, contributing editor

Quantel Completes Acquisition of Ellex

By Jerry Helzner, contributing editor

iStent Shows 6-Year Effectiveness

By Jerry Helzner, contributing editor

iStent inject Effective in Normal-Tension Glaucoma

By Jerry Helzner, contributing editor

Effect of Diet on Glaucoma Prevention

By Jerry Helzner, contributing editor

First Eye Success With Xen Predicts Fellow Eye Success

By Jerry Helzner, contributing editor

Vitamin B3 Shows Potential in Protecting Against Glaucoma Damage

By Jerry Helzner, contributing editor

Virus Adversely Affects Elective MIGS Procedures

By Jerry Helzner, contributing editor

New App Covers Ophthalmic Acronyms

By Jerry Helzner, contributing editor